Karyopharm Therapeutics Files For Shelf Registration Of Up To 45.8M Shares Of Common Stock By Selling Stockholders
$KPTI
Biotechnology: Pharmaceutical Preparations
Health Care
- SEC Filing
- SEC Filing
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/19/2023 | $8.00 | Overweight | Piper Sandler |
| 11/4/2022 | $7.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 3/8/2022 | $12.00 → $8.00 | Sector Perform | RBC Capital |
| 3/2/2022 | $8.00 → $6.00 | Market Perform | SVB Leerink |
| 2/9/2022 | $8.00 | Underweight → Neutral | JP Morgan |
| 1/10/2022 | $6.00 → $8.00 | Market Perform | SVB Leerink |
| 12/9/2021 | $8.00 → $9.00 | Sector Perform | RBC Capital |
| 11/19/2021 | $27.00 → $10.00 | Overweight → Equal-Weight | Morgan Stanley |
– Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out Remains on Track for 2H 2025 – – Narrows Full-Year 2024 Total Revenue Guidance Range to $145.0 Million to $155.0 Million; U.S. XPOVIO Net Product Revenue Guidance Range to $110.0 Million to $115.0 Million; R&D and SG&A Expense Guidance Range to $255.0 Million to $265.0 Million – NEWTON, Mass., Nov. 5,
-- Conference Call Scheduled for Tuesday, November 5, 2024, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2024 financial results on Tuesday, November 5, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Tuesday, November 5, 2024, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (
Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA Spleen Volume Response Rate ≥ 35% (SVR35) Remains a Co-primary Endpoint Promising Improvement in Abs-TSS and SVR35 from Phase 1 Trial of Selinexor in Combination with Ruxolitinib Adds Confidence in Phase 3 SENTRY Trial Proactively Increasing Total Sample Size of the SENTRY Trial to Approximately 350 Patients to Further Increase the Statistical Powering; Expected Top-line Data Read-out Remains in 2H 2025 Company to Host a Conference Call Today at 8:00 a.m. ET Featuring Drs. Raajit Rampal and John Mascarenhas NEWTON, Mass., Oct. 31, 2024
NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t
NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the Board of Directors at Marengo Therapeutics, Inc., a company pioneering novel T-cell targeting therapeutics to fight cancer. "Dr. Su is a physician‐scientist and pharmaceutical industry leader who brings tremendous experience guiding products thro
DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs. Ms. Lewis currently serves as the Chief Development Operations Officer at Replimune Group, Inc. where she has oversight for development of an integrated clinica
8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
S-8 - Karyopharm Therapeutics Inc. (0001503802) (Filer)
NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t
NEWTON, Mass., Nov. 18, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced abstracts detailing selinexor data have been selected to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego, CA. "We are pleased to share presentations on selinexor at this year's annual meeting," said Reshma Rangwala, MD, PhD, Chief Medical Officer and Head of Research at Karyopharm. "The data being presented dem
– Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out Remains on Track for 2H 2025 – – Narrows Full-Year 2024 Total Revenue Guidance Range to $145.0 Million to $155.0 Million; U.S. XPOVIO Net Product Revenue Guidance Range to $110.0 Million to $115.0 Million; R&D and SG&A Expense Guidance Range to $255.0 Million to $265.0 Million – NEWTON, Mass., Nov. 5,
Piper Sandler initiated coverage of Karyopharm Therapeutics with a rating of Overweight and set a new price target of $8.00
RBC Capital Mkts upgraded Karyopharm Therapeutics from Sector Perform to Outperform and set a new price target of $10.00 from $7.00 previously
RBC Capital reiterated coverage of Karyopharm Therapeutics with a rating of Sector Perform and set a new price target of $8.00 from $12.00 previously
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price target from $8 to $7.
HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 price target.